TuHURA Biosciences, Inc./NV (HURA): M&A transaction — Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA

TuHURA Biosciences, Inc./NV

Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).
1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.
CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.
Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025.

item 2.01 item 1.01 item 9.01 item 5.02 item 2.02 item 3.03 item 5.01 item 5.03 item 5.06 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TuHURA Biosciences, Inc./NV: Kintara ceased to be a shell company as a result of the Merger.

Change: shell status

Exact text from the filing

As a result of the Merger, Kintara ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TuHURA Biosciences, Inc./NV: Company changed its fiscal year end from June 30 to December 31.

Change: fiscal year change

Exact text from the filing

In connection with the closing of the Merger, the Company changed its fiscal year end from June 30 to December 31, the fiscal year end of TuHURA prior to the Merger.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TuHURA Biosciences, Inc./NV underwent a change of control (closed 2024-10-18).

Action: change of control
Closing: 2024-10-18

Exact text from the filing

On October 18, 2024, the Nevada corporation formerly known as "Kintara Therapeutics, Inc." completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger, dated as of April 2, 2024

View on SEC.gov

24 governance changes filed in the last 30 days. Browse all governance changes →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-24-115765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.